Bristol Myers Squibb stock heads into the open after a 0.6% NYSE dip
Published on 09/16/2026 at 08:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock closed at USD 63.69 on the New York Stock Exchange on September 15, 2026, marking a 0.64% decline versus the previous session in regular trading. The move left the shares trading within a narrow intraday band around the mid-USD 60s and broadly in step with a weaker wider U.S. equity market that day.
September 15, 2026 in numbers
Bristol Myers Squibb Co. (ISIN US0897961004, NYSE: BMY) finished the September 15, 2026 session at USD 63.69 on the New York Stock Exchange, down 0.64% from the prior close in regular trading according to MarketBeat data. Per the same NYSE overview, the stock changed hands close to the USD 64 mark during the day, with the last regular-session print at 3:59 p.m. Eastern followed by marginally higher extended trading indications at USD 63.75 later in the evening, underscoring a relatively contained price range for the session.MarketBeat On the same day, a broader U.S. equity benchmark such as the tech-heavy Nasdaq Composite also slipped, with Zacks reporting a 0.6% loss for the Nasdaq Composite to close at 26,186.41, highlighting that the modest decline in Bristol Myers Squibb coincided with a softer broader market tone.
Session volume for Bristol Myers Squibb on September 15, 2026 was reported near typical recent levels in NYSE trading, with the share price remaining just below a market capitalization of roughly USD 130.93 billion that had been recorded two days earlier at a close of USD 64.08 on September 14, 2026.CompaniesMarketCap That earlier session on September 14, 2026 had seen Bristol Myers Squibb stock add 0.69% in regular trading to reach USD 64.08 on the NYSE, leaving the shares a few dollars below prevailing analyst consensus price targets around the mid-USD 60s, as noted in a corporate-news wrap.Ad-hoc-news
Legal dispute and data in focus today
Today, September 16, 2026, attention around Bristol Myers Squibb is shaped in part by ongoing legal and pipeline developments rather than a scheduled earnings release. As Reuters reported on September 15, 2026, Bristol Myers Squibb and its partner Ono Pharmaceutical filed suit in Delaware federal court seeking to block a proposed U.S. biosimilar version of their Opdivo immunotherapy, a case that keeps the company’s immuno-oncology franchise and intellectual-property strategy in the spotlight as trading resumes.
In addition, investor focus today remains on updated earnings expectations and pipeline data discussed in recent days. A Zacks Research note relayed by MarketBeat on September 15, 2026 highlighted a positive outlook for Bristol Myers Squibb’s third-quarter earnings, citing an FY 2026 earnings-per-share guidance range of 6.750 to 7.000 and underscoring that consensus expectations and guidance remain central reference points for the stock ahead of the next results release. Earlier in September 2026, an article on Yahoo Finance outlined encouraging Phase 2 data from the QUINTESSENTIAL trial of the company’s GPRC5D-directed CAR T candidate arlocabtagene autoleucel in heavily pretreated multiple myeloma patients, noting that the study met its primary and key secondary response endpoints with a safety profile in line with existing CAR T therapies, an update that continues to frame sentiment around Bristol Myers Squibb’s cell-therapy pipeline as investors look ahead to forthcoming regulatory and clinical milestones.Yahoo Finance
